Trials / Completed
CompletedNCT07462949
A Study on Median Effective Concentration of Ciprofol Combined With Remifentanil Via Target-controlled Infusion for Inhibiting Tracheal Intubation Stimulation Under qNOX Index Monitoring
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 70 (actual)
- Sponsor
- Guangzhou General Hospital of Guangzhou Military Command · Academic / Other
- Sex
- All
- Age
- 19 Years – 55 Years
- Healthy volunteers
- Not accepted
Summary
1. The combined induction of intubation with propofol and remifentanil is widely used in clinical anesthesia, primarily through a single intravenous injection. Target-controlled infusion (TCI) technology, which combines pharmacology with clinical practice, offers a more stable and precise infusion mode; 2. This project aims to explore the half-effective concentration (EC50) of propofol combined with remifentanil for inhibiting tracheal intubation stimulation through a sequential approach under the monitoring of qNOX pain index.
Detailed description
Patients undergoing elective surgery, aged 19 to 55 years, with ASA I or II, were selected for a sequential trial in two stages: 1. In the first stage, induction dose of ciprofol was fixed at 0.4 mg/kg, and the EC50 and EC95 of remifentanil were measured. 2. In the second stage, the EC95 of remifentanil was fixed, and the EC50 and EC95 of ciprofol were measured. The EC and 95% confidence interval (CI) were calculated using the probit probability unit method. 3. Additionally, the effectiveness of the qNOX index in guiding tracheal intubation stimulation was evaluated by analyzing the receiver operating characteristic (ROC) curves.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cipofol combined with remifentanil administered via target-controlled infusion | Cipofol combined with remifentanil administered via target-controlled infusion for inhibiting tracheal intubation stimulation in adults under qNOX pain index monitoring. |
Timeline
- Start date
- 2026-03-03
- Primary completion
- 2026-04-03
- Completion
- 2026-04-06
- First posted
- 2026-03-10
- Last updated
- 2026-04-17
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07462949. Inclusion in this directory is not an endorsement.